Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

BioLineRx Announces Positive Preliminary Results From The Phase I/II Trial Of BL-1040
BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, today announced positive preliminary results from the ongoing phase I/II clinical trial designed to assess the safety and feasibility of BL-1040, the first injectable device designed to address cardiac remodeling, in 20- 30 patients at several sites in Germany and Belgium. To date, 15 patients were successfully treated with BL-1040 with no complications. Moreover, six months follow up results from the first 5 patients show BL-1040"s efficacy in preventing cardiac remodeling and preserving cardiac function.
generic viagra online
Declaration Of H1N1 Pandemic To Accelerate H1N1 Vaccine Production
The WHO"s decision Thursday to declare H1N1 (swine) flu a pandemic will "speed the production of a vaccine against the new virus," however scientists continue to caution that "it will be fall at the earliest before the first doses are available," the Los Angeles Times reports.
News of the day
Induced Pluripotent Stem Cells Repair Heart
In a proof-of-concept study, Mayo Clinic investigators have demonstrated that induced pluripotent stem (iPS) cells can be used to treat heart disease. iPS cells are stem cells converted from adult cells. In this study, the researchers reprogrammed ordinary fibroblasts, cells that contribute to scars such as those resulting from a heart attack, converting them into stem cells that fix heart damage caused by infarction. The findings appear in the current online issue of the journal Circulation.
Health Insurance

Research-based Pharmaceutical Industry's Health Contribution Presented To Special United Nations Session On Health In Africa And Other Countries

The IFPMA was invited to attend a special session of the United Nations (UN) in Geneva on health in Africa and other least developed countries, organized by the UN Economic and Social Commission (ECOSOC). Michael D. Boyd, Acting Director General of the IFPMA, gave a briefing on the research-based pharmaceutical industry"s contribution to improving health in the developing world, speaking to an audience which included foreign ministers of UN Member States and senior UN officials. Mr. Boyd commented: "A quiet transformation has been going on over the last decade or so, strengthening links between the developed world and least developed countries, especially in the area of health. As a single industry sector, the IFPMA"s member companies have made an unprecedented contribution to improving health in the countries which have the greatest needs." Since the inception of the UN Millennium Development Goals, through to the end of 2007, IFPMA member companies made available enough medical assistance to reach nearly 2 billion people in low and middle income countries - assistance conservatively valued at USD 9.2 billion(1). The growing range of industry-backed partnership programs to help improve health in developing countries is documented in an annual IFPMA partnerships book(2) and in a searchable online database, at http://www.ifpma.org/healthpartnerships. The research-based pharmaceutical industry has also been steadily increasing its R&D into diseases of the developing world. In 2005, IFPMA Member Companies were working on 32 new medicine projects for the top 10 diseases of the developing world; this year, they are working on 75 such projects(3) . The research-based pharmaceutical industry"s commitment to help develop new medicines for the developing world is underlined by the existence of five company R&D centers which are dedicated purely to research into diseases which disproportionately affect developing countries(4). (1) See here. (2) Partnerships to Build Healthier Societies in the Developing World - May 2009. See here. (3) See here. (4) Industry Dedicated DDW R&D Centers: - AstraZeneca, Bangalore Research Institute, India (Tuberculosis) - GlaxoSmithKline, DDW Drug Discovery Center, Tres Cantos, Spain (Malaria, Tuberculosis, Kinetoplastids) - Lilly (+ Merck & Co., Inc.), Lilly TB Drug Discovery Initiative, Seattle, USA, (Tuberculosis) - Novartis, Novartis Institute for Tropical Diseases, Singapore (Dengue Fever, Malaria, Tuberculosis) - Novartis, Novartis Vaccines Institute for Global Health, Siena, Italy (Diarrheal diseases, Salmonella). IFPMA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009